FORM 6-K
 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending February 2009
 

GlaxoSmithKline plc
(Name of registrant)
 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 
Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

 

 
 
 
Notification of Transactions of Directors and
Persons Discharging Managerial Responsibility
 
Vesting of awards made under GlaxoSmithKline's share plans in 2006
 
This notification, prepared in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a), sets out the vesting of share options made in 2006, under the GlaxoSmithKline Share Option Plan.
 
The three-year performance period for the GlaxoSmithKline Share Option Plan awards made to appointed CET members in 2006, at an option price of £14.68 (or US$51.02 in the case of ADSs), which commenced on 1 January 2006, came to an end on 31 December 2008. The performance conditions for this grant were not fully met for awards made to the then Executive Directors and CET members who are all persons discharging managerial responsibility. The Remuneration Committee of the Board of GlaxoSmithKline therefore confirmed that 50.7% of the original grant was exercisable.
 
 

 
 
Number of options over Shares/ADSs exercisable
 
Shares
ADSs
Mr A P Witty*
89,993
 
Mr J S Heslop*
117,117
 
Mr J M Clarke
89,993
 
Mr M Dunoyer
35,490
 
Mr D J Phelan
 
44,997
Mr D Pulman
 
29,153


* denotes an Executive Director
 
 
Grants made in 2006, to senior executives who have since been appointed Executive Directors or CET members were not subject to performance conditions. The Remuneration Committee therefore confirmed that the whole of the original grant was exercisable.
 
 

 
 
Number of options over Shares/ADSs exercisable
 
Shares
ADSs
Dr M Slaoui*
68,520
 
Mr S M Bicknell
12,650
 
Mr E J Gray 
26,800
 
Mr D Learmouth
12,650
 
Mr D S Redfern
26,800
 
Ms C Thomas
20,180
 
Mr J R Stephenne
 
68,520
 
 
Mr W C Louv
 
11,870


*denotes an Executive Director
 
The Company, Directors, and Persons Discharging Managerial Responsibility were advised of these transactions on 23 February 2009.
 
V A Whyte
Deputy Company Secretary
 
24 February 2009
 

Enquiries:
 
 
 
UK Media enquiries:
Philip Thomson
(020) 8047 5502
 
David Outhwaite
(020) 8047 5502
 
Stephen Rea
(020) 8047 5502
 
 
 
US Media enquiries:
Nancy Pekarek
(919) 483 2839
 
Mary Anne Rhyne
(919) 483 2839
 
Kevin Colgan
(919) 483 2839
 
Sarah Alspach
(215) 751 7709
 
 
 
European Analyst/Investor enquiries:
David Mawdsley
(020) 8047 5564
 
Sally Ferguson
(020) 8047 5543
 
Gary Davies
(020) 8047 5503
 
 
 
US Analyst/ Investor enquiries:
Tom Curry
(215) 751 5419
 
Jen Hill
(215) 751 7002


 
 
 

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: February 24 2009

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc